Enzastaurin
- Generic Name
- Enzastaurin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H29N5O2
- CAS Number
- 170364-57-5
- Unique Ingredient Identifier
- UC96G28EQF
- Background
Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.
- Indication
Investigated for use/treatment in brain cancer, lymphoma (non-hodgkin's), and lung cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Glioblastoma Clinical Trials 2024: EMA, PDMA, FDA Approvals
DelveInsight's 'Glioblastoma Pipeline Insight, 2024' report details 190+ companies developing 200+ therapies, including Enzastaurin, Marizomib, VT1021, and ONC201, with insights on mechanism of action, route of administration, and market dynamics.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath